Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:15:30.838Z.
Calculation as of: 2026-10-06T14:15:30.838Z.
Quote observation: 2026-10-06T14:15:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f621ea2a381ac0066d385c57ed104ff22630177ee14cd635e65ed0429d7856c2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Aclaris Therapeutics, Inc.
Market Cap
$560.05M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$562.72M
Price/FCF Ratio
N/A
TTM Avg
16.85
3Y Avg
16.85
5Y Avg
16.85
Market Cap
$549.35M
Price/FCF Ratio
N/A
TTM Avg
67.09
3Y Avg
65.49
5Y Avg
24.64
Market Cap
$564.17M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$536.12M
Price/FCF Ratio
30.62
TTM Avg
34.94
3Y Avg
46.00
5Y Avg
46.00
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | $560.05M | N/A | N/A | N/A | N/A |
| MiniMed Group, Inc. (MMEDV)vs › | $560.00M | N/A | N/A | N/A | N/A |
| Aquestive Therapeutics, Inc. (AQST)vs › | $562.72M | N/A | 16.85 | 16.85 | 16.85 |
| CorMedix Inc. (CRMD)vs › | $562.66M | 2.25 | 8.28 | 11.19 | 11.19 |
| CytomX Therapeutics, Inc. (CTMX)vs › | $549.35M | N/A | 67.09 | 65.49 | 24.64 |
| BlossomHill Therapeutics, Inc. (BLSM)vs › | $564.17M | N/A | N/A | N/A | N/A |
| Delcath Systems, Inc. (DCTH)vs › | $536.12M | 30.62 | 34.94 | 46.00 | 46.00 |
| OrthoPediatrics Corp. (KIDS)vs › | $585.02M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $530.42M | N/A | N/A | N/A | N/A |
| Immix Biopharma, Inc. (IMMX)vs › | $524.43M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
